Abstract:1,4-dihydropyrimidine-2-thiones were synthesized in five series that include 5-carboxylic acid derivatives of dihydropyrimidine (series A, 6 – 8 ), novel 5-carboxamide derivatives of dihydropyrimidine (series B, 9 – 14 ), N,S - dimethyl - dihydropyrimidine (series C, 15 – 20) , N -hydrazinyl derivatives of dihydropyrimidine (series D, 21 – 24) and tetrazolo dihydropyrimidine derivatives (series E, 25 – 28 ), and evaluated for anti-diabetic capability. The prepared novel compounds were structurally established by FTIR, 1 HNMR, 13 CNMR, ESI and HRMS. All of these compounds from series A - E were first time examined for α-glucosidase inhibition as to evaluate their anti-diabetic potential. Most of the compounds for example 8, 11 – 14, 15, 17 – 21, 25 and 28 demonstrated greater α-glucosidase inhibitory effects (IC 50 = 12.5 ± 0.21 to 47.3 ± 0.23 μM) when compared to deoxynojirimycin as standard (IC 50 = 52.02 ± 0.36 μM). Compounds from series B and C found to be highly active however, the compounds from series D found generally less active. The structure–activity relationships demonstrated the importance of C-5 carboxamides, C-5 ethyl ester functionality, and the presence of N,S-dimethyl groups at pyrimidine ring for α-glucosidase inhibition. The docking studies demonstrated that all the active compounds have van der Waal and alkyl bonds interactions with the targeted site of the human lysosomal acid α −glucosidase. All these compounds were also tested for antioxidant potential by DPPH radical scavenging protocol that exhibited significant antioxidant effects (IC 50 = 21.4 ± 0.45 to 92.1 ± 0.38 μM) as compared to the standard butylated hydroxyanisol (IC 50 = 44.2 ± 0.36 μM). Among all, compound 13, 14 and 19 with potent α-glucosidase inhibition (IC 50 = 18.9 ± 0.72, 23.3 ± 0.45 and 21.5 ± 0.16 μM, respectively) along with excellent antioxidant potential in the range of (IC 50 = 21.4 ± 0.45 to 31.2 ± 0.23 μM) indicated their ability to use as valuable leads for the development of anti-diabetic drugs with the combined effects of antioxidants.

Synthesis and Biological Activity of Novel Deoxynojirimycin Derivatives As Potent Alpha-Glucosidase Inhibitors

ChemInform Abstract: Synthesis and Biological Activity of Novel Deoxynojirimycin Derivatives As Potent Α‐glucosidase Inhibitors.

Synthesis and Evaluation of Phenyltriazole-Deoxynojirimycin Hybrids as Potent α-Glucosidase Inhibitors

Design, Synthesis and Biological Evaluation of Novel Pyrimidinedione Derivatives As DPP-4 Inhibitors.

Synthesis and glycosidase inhibition of 5-C-alkyl-DNJ and 5-C-alkyl-l-ido-DNJ derivatives

Inhibition Mechanism of Α-Glucosidase by Three Geranylated Compounds: Kinetic, Spectroscopic and Molecular Docking

Research Progress in Origin and Synthesis of 1-Deoxynojirimycin

1-Deoxynojirimycin and its Derivatives: A Mini Review of the Literature

Chemical synthesis, inhibitory activity and molecular mechanism of 1-deoxynojirimycin–chrysin as a potent α-glucosidase inhibitor

Synthesis, highly potent α-glucosidase inhibition, antioxidant and molecular docking of various novel dihydropyrimidine derivatives to treat diabetes mellitus

[Synthesis, Biological Activity and Molecular Docking Research of N-{[(4-oxo-thiochroman-3-yl)phenyl]-methyl}acetamide Derivatives As Α-Glucosidase Inhibitors].

Multivalent glucosidase inhibitors based on perylene bisimide and iminosugar conjugates

Novel carbazole-oxadiazole derivatives as anti-α-glucosidase and anti-α-amylase agents: Design, synthesis, molecular docking, and biological evaluation

Nanomolar β-glucosidase and β-galactosidase inhibition by enantiomeric α-1- C -alkyl-1,4-dideoxy-1,4-imino-arabinitol derivatives

New cycloalkyl[b]thiophenylnicotinamide-based -glucosidase inhibitors as promising anti-diabetic agents: Synthesis, in silico study,<i> in</i><i> vitro</i> and<i> in</i><i> vivo</i> evaluations

Synthesis, biological evaluation, and molecular modelling of novel quinoxaline-isoxazole hybrid as anti-hyperglycemic

Design, Synthesis and Biological Evaluation of Novel (E)-2-benzylidene-n-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)hydrazine-1-carboxamide Derivatives As Α-Glucosidase Inhibitors.

Novel cinnamic acid magnolol derivatives as potent α-glucosidase and α-amylase inhibitors: Synthesis, in vitro and in silico studies

Discovery of new 2-phenyl-1H-benzo[d]imidazole core-based potent α-glucosidase inhibitors: Synthesis, kinetic study, molecular docking, and in vivo anti-hyperglycemic evaluation

Preparation of Novel 3,4,5‐Triaryl‐1,2,4‐Oxadiazole Derivatives: Molecular Docking and α‐Glucosidase assessment

Design, synthesis, biological evaluation, and docking study of chromone-based phenylhydrazone and benzoylhydrazone derivatives as antidiabetic agents targeting α‐glucosidase